Skip to content
MedsAcross

Medicine

Jardiance 25 mg tablet

Empagliflozin · Oral · Boehringer Ingelheim Pharmaceuticals
Available on requestPrescription onlyUS FDA

Jardiance 25 mg tablet is a prescription medicine containing Empagliflozin for oral use, marketed by Boehringer Ingelheim Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C…

Key facts

Active ingredient (INN)
Empagliflozin
Brand
Jardiance
Strength
25 mg
Dosage form
Tablet
Route
Oral
Packs
30 tablets, 30 blister pack, 90 tablets and 11 more
Marketing authorisation holder
Boehringer Ingelheim Pharmaceuticals
Manufacturers
Boehringer Ingelheim PharmaceuticalsAphena Pharma Solutions - TennesseeA-S Medication SolutionsCardinal HealthRedpharm Drug
Origin register
US FDA, United States
Storage
Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F).
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
A10BK03 Empagliflozin
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
1 August 2014
Identifiers
RxCUI 1545658, 1545664, 1545666 +1DailyMed set ID faf3dd6a-9cd0-39c2-0d2e-232cb3f67565, a77214ca-572e-485e-aae9-f7950187e5fb, f2b41c77-0abb-40ee-8578-86a748d0e19e +3NDC 0597-0153, 50090-4384, 50090-6457 +3Application NDA204629

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
30 tablet, film coated in 1 bottle0597-0153-30Boehringer Ingelheim Pharmaceuticals1 August 2014
30 blister pack in 1 carton / 1 tablet, film coated in 1 blister pack0597-0153-37Boehringer Ingelheim Pharmaceuticals1 August 2014
90 tablet, film coated in 1 bottle0597-0153-90Boehringer Ingelheim Pharmaceuticals1 August 2014
90 tablet, film coated in 1 bottle50090-4384-0A-S Medication Solutions25 June 2019
30 tablet, film coated in 1 bottle50090-4384-1A-S Medication Solutions6 August 2023
90 tablet, film coated in 1 bottle50090-6457-0A-S Medication Solutions1 May 2023
9000 tablet, film coated in 1 bottle71610-177-09Aphena Pharma Solutions - Tennessee24 October 2018
15 tablet, film coated in 1 bottle71610-177-15Aphena Pharma Solutions - Tennessee18 September 2019
1800 tablet, film coated in 1 bottle71610-177-42Aphena Pharma Solutions - Tennessee9 December 2022
45 tablet, film coated in 1 bottle71610-177-45Aphena Pharma Solutions - Tennessee3 October 2019
1080 tablet, film coated in 1 bottle71610-177-81Aphena Pharma Solutions - Tennessee22 April 2025
5040 tablet, film coated in 1 bottle71610-177-99Aphena Pharma Solutions - Tennessee27 October 2025
990 tablet, film coated in 1 bottle, plastic55154-0412-8Cardinal Health1 August 2014
30 tablet, film coated in 1 bottle67296-2324-3Redpharm Drug1 August 2014

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 1 August 2014Drugs@FDA
EU (EMA)AuthorisedEMA medicines data
India (CDSCO)Not yet confirmed against CDSCO approval lists—
AustriaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BelgiumRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BulgariaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CroatiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CyprusRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CzechiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
DenmarkRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
EstoniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FinlandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FranceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GermanyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GreeceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
HungaryRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IcelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IrelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
ItalyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LatviaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LiechtensteinRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LithuaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LuxembourgRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
MaltaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NetherlandsRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NorwayRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PolandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PortugalRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
RomaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SlovakiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SloveniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SpainRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SwedenRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Other strengths and forms of Empagliflozin

Clinical summary

Empagliflozin is a sodium-glucose cotransporter 2 inhibitor indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. It is available as tablets for oral use. MedsAcross supplies Empagliflozin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Empagliflozin

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Jardiance 25 mg tablet for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.